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Abstract. We provide a detailed report of a reproduction study of a
paper published in the International Journal of Medical Sciences (IJMS).
We first use the PROV-O ontology to model our reconstruction of the
computational workflow of the original experiment and to systematically
explicate all information that is needed for an reproduction study. We
then identify which part of the required information is published in the
IJMS paper and what part is missing. We then discuss our reproduction
of this workflow, following the original as much as possible. Again, we
use PROV-O to precisely define our version of the workflow, including
our version of the information that was missing in the IJMS paper of
the study. Finally, we generalize from the specific cased described in the
original paper by providing a web service that allows mining for arbitrary
drug-adverse event pairs.
1 Introduction
Reproducing scientific results is often more an art than science. By describing
a concrete case study we show how we used PROV-O to systematically analyse
a paper from a different field, written by authors we do not personally know.
We attempt to reconstruct the provenance graph of the original experiment by
carefully studying the description of the method, the statistics and the results
provided either directly in the paper or other sources that the paper refers to.
We formalized our reconstruction using the PROV-O ontology. The formalization
makes the dependencies between the intermediate steps explicit, which should
allow us to systematically investigate how the results presented in the paper
were computed. To reproduce the results we need to understand the input and
output behavior of the computations modeled by the prov:Activity nodes. The
properties of the input and output prov:Entity can help to verify wether this
understanding is correct.
The paper we selected is the Open Access article Adverse Event Profiles of
5-Fluorouracil and Capecitabine: Data Mining of the Public Version of the FDA
Adverse Event Reporting System, AERS, and Reproducibility of Clinical Obser-
vations published in the International Journal of Medical Sciences (IJMS) [12].
The paper describes a computational data mining study on public data and ap-
pears to be a good candidate for a reproduction study. We use this paper as a
case study to provide insights in the problem of reproducing scientific results,
we do not aim to criticize this particular paper in any way.
The topic of the paper is an example of pharmacovigilance which is defined
by the World Health Organization as “the science and activities relating to the
detection, assessment, understanding and prevention of adverse effects or any
other medicine-related problem”3. Computational studies play an important role
in Pharmacovigilance to detect drug side-effects. Such studies are an economic
way to generate hypotheses before performing costly clinical reviewing [13]. The
IJMS paper [12] follows a typical scenario in pharmacovigilance: the use of a
database with reports of adverse events (AE) to find disproportional correlations
between a drug and an adverse reaction. In this example, the Adverse Event
Reporting System of the US Food and Drug Administration (FAERS) is used to
compare adverse effects of drugs.
While the FAERS database itself is publicly available, it is not trivial to
reproduce the results of the experiments that use this database. Results and
tools are described in scientific publications, but tools and (intermediate) results
are typically not available. Our case study demonstrates in detail what prevents
reproduction. From the observations of this study we derive initial requirements
to support studies of drug side-effects that can be fully reproduced.
2 Related work
This section gives a brief overview of related work on data publication, scientific
workflows and provenance.
The requirement for reproducibility [14] has been a key motivator for an
increased interest in data sharing and publication, especially in fields dealing
traditionally with ever growing datasets, e.g. [1]. Even though data sharing does
not always immediately benefit the individual researcher, the potential for the
scientific community is significant [15]. Funding agencies, keen on maximizing
impact and reducing fraud, are now actively requiring data sharing. For exam-
ple, both the US National Science Foundation and the EU now require data
management plans for all proposals they consider.4 Note that also in areas that
focus on human action, such as in human computer interaction, replication has
part of the research agenda5.
However, as becomes clear in this paper as well, raw data publication (such as
FAERS) is in itself not sufficient for reproducible research. Data often needs to
be moulded and transformed to a new data model before it becomes suitable for
answering a particular research question. This data preparation step can take
between 60 to 80% of data-oriented research tasks [6]. Workflow systems [4],
provide mechanisms for reproducing scientific conclusions, based on shared data.
3 http://www.who.int/medicines/areas/quality_safety/safety_efficacy/
pharmvigi/en/
4 See http://www.nsf.gov/bfa/dias/policy/dmp.jsp and
http://europa.eu/rapid/press-release_SPEECH-13-236_en.htm
5 http://www.cs.nott.ac.uk/~mlw/replichi.php
The benefit for individual researchers publishing a workflow, is that workflows
are executable procedures that can be run against various inputs. Workflows can
be shared and reused through social platforms such as myExperiment6. Curated
workflow descriptions [8] combined with original data, can serve as self-contained
research objects [3].
There are, however, two drawbacks to using a workflow system. Firstly, work-
flow descriptions are inevitably tied to the system used, and thus constrained
to the types of operations supported by the system. Secondly, not all steps of
interest in a scientific research process are necessarily of a computational nature,
e.g. consider the information conveyed through the reuse of texts in scientific
discourse. Though in its early stages, work on automatic provenance reconstruc-
tion [10] is a promising approach to making explicit the temporal and causal
dependencies between individual elements of scientific output.
The overarching requirement for reproducible research is an explicit account
of what processes and activities led from original input, albeit data, texts, other
media, to the contribution of a scientific publication. The PROV standard of
the W3C [11], based on ten earlier provenance models, such as the Open Prove-
nance Model7 and the Provenance Vocabulary8, provides a standard vocabulary
and semantics for expressing plans (workflows), process execution, dependencies
between entities and processes, and agent involvement. The PROV-O ontology
is a vocabulary for expressing PROV as Linked Data.9 Most scientific workflow
systems allow provenance tracking of workflow execution, and allow exporting
it to PROV or a compatible format. The consumption of provenance informa-
tion by applications is gradually receiving more attention [9]. The ProvBench
repository10 has the objective to bootstrap the development of systems for the
visualization, analysis and understanding of provenance graphs.
3 Basic concepts in Pharmacovigilance
Various organizations maintain reporting systems of adverse events. The World
Health Organization (WHO) maintains vigiBase, the US Food and Drug Admin-
istration (FDA) maintains the Adverse Event Reporting System (FAERS) and
many countries maintain their own system. These organisations provide func-
tionality for medical professionals to submit reports of adverse events that they
encountered with their patients. A report in the FAERS database contains a
list of the medication that the patient received and a list of adverse events. In
addition it may contain information about the patient such as the gender and
age. Unique of the the FAERS database is that it is publicly available on the
Web. XML and CSV files for every yearly quarter starting at 2004 are available
for download.
6 See http://www.myexperiment.org
7 See http://purl.org/net/opmv/ns
8 See http://purl.org/net/provenance/ns
9 See http://www.w3.org/TR/prov-o/.
10 https://sites.google.com/site/provbench/
Adverse event databases are used in pharmacovigelance research to detect
side effects of drugs. An important part of this research focusses on the detec-
tion of side effects of new drugs that appear on the market. The WHO has an
extensive program for this research3, and involves large scale data mining of
adverse event databases. Other research focusses on the side effects of sets of
specific drugs. These studies are typically motivated by clinical evidence.
Both types of research depend on methods to detect a disproportional correla-
tion between a drug and an associated adverse event. The most common methods
are the proportional reporting ratio (PRR), the reporting odds ratio (ROR), the
information component (IC) and the empirical Bayes geometric mean (EBGM).
All are based on the expected frequency relative to all drug event pairs that are
available in the database. Calculating signals with these methods requires a 2x2
contingency table, as shown in Table 1. This table contains (a) the number of
mentions of a drug together with a mention of a reaction (an adverse event), (b)
the number of mentions of all other drugs and that reaction, (c) the number of
mentions of the drug and all other reactions and (d) the number of mentions of
all other drugs and all other reactions. According to [5] the PRR is calculated
from this table using Eq. 1.
PRR =
a/(a+ c)
b/(b+ d)
(1)
The expected value for a PRR is one and values above it indicate the strength
of the association. In addition, the strength of a statistical association can be
calculated using a standard chi-squared test.
χ2 =
(ad− bc)2(a+ b+ c+ d)
(a+ b)(c+ d)(b+ d)(a+ c)
(2)
According to [5] a signal is detected between a drug and an adverse event if
the PRR is at least 2, the chi-squared is at least 4 and there are at least 3 or
more cases mentioning the drug and the event. We refer to the literature for the
details of ROR [16], IC [2] and EBGM [17]. A comparison of these methods is
reported in [18].
To compute the 2x2 contingency table one needs to collect all mentions of
a particular drug and a particular adverse event. Collecting the adverse event
mentions is straightforward because in the FAERS database they are consistently
identified with the preferred terms from the Medical Dictionary for Regulatory
Activities11 (MedDRA). The drug names in the FAERS database are, however,
not standardized. The same drug may be entered in to the database in various
forms. For example, drug names are entered with or without dosage information,
method (e.g. oral, injection) and other additions. Some have entered the drug
name, while others used the brand or trade name and again others the active
ingredient. There are various spelling variations and synonyms. To properly fill
the 2x2 contingency table one has to deal with the variations in drug names.
11 http://www.meddramsso.com/
Drug of interest All other drugs
Reaction of interest a b a+b
All other reactions c d c+d
a+c b+d a+b+c+d
Table 1. 2x2 contingency table to calculate disproportionality measurements (adapted
from [5]).
4 Case study
Our target IJMS paper [12] investigates the so called safety profiles of two types
of drugs that are used in the treatment of cancer. The first drug is 5-Fluorouracil
(5-FU), which was traditionally used for the treatment of solid tumors. This drug
was given by injection or infusion. Due to the high risks and costs of this type
of treatment the pharmaceutical industry developed a class of drugs known as
oral fluoropyrimidines, from which Capecitabine is the most well known one.
Clinical trials that compared the use of Capecitabine against 5-FU favor the use
of the first. Due to limitations of the clinical trials the picture is, however, not
complete. For example, the trials do not provide evidence for adverse events that
occur at relative low frequencies. The aim of the paper is to test the conclusions
drawn from the trials and provide additional evidence for lower frequency adverse
events.
In the IJMS paper the authors describe the method to detect the signals
for Capecitabine and 5-FU with various adverse events. As a first step towards
reproduction of this study we formalized the steps and their dependencies using
the PROV-O ontology. In addition, we describe the information provided in the
paper that could help in the reproduction.
4.1 Provenance reconstruction
Figure 1 in Appendix A shows a reconstruction of the provenance graph for the
computation of the PRR for 5-FU with the adverse event Leukopenia and the
PRR of Capecitabine with Leukopenia.
Original FDA datasources The workflow starts at the bottom with datasources
obtained from the FDA. The website of the FDA contains ZIP files for each
yearly quarter12. For each quarter there are two versions available, ASCII and
SGML. The former contains a dump of the database in the form of 7 CSV files,
while the latter contains a single SGML file. The authors of the IJMS paper used
the ASCII versions for the first quarter of 2004 up to the last quarter of 2009, a
12 http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/
Surveillance/AdverseDrugEffects/ucm083765.htm
total of 24 files. In the provenance graph the quarterly files are represented by
individual nodes, but for the sake of clarity we do not show all nodes. The ZIP
files from the FDA contain a document that describes the structure of the CSV
files and instructions how to interpret them.
Report aggregation The paper mentions that the total dataset contains 2,231,029
reports. From this we conclude that an aggregation step was performed. In the
provenance graph the aggregated dataset is represented by the node with the
label A.FAERS. This aggregated dataset is the starting point for two cleanup
activities. First, the authors removed superfluous reports as the data contains
updated versions of a report as separate records. The paper refers to the doc-
umentation from the FDA in which it is advised to keep only the most recent
report for a specific case. The resulting dataset is labeled B.FAERS in the prove-
nance graph, and contains (according to the paper) 1,644,220 reports.
Drug name normalization In the second cleanup step the drug names are nor-
malized: all drug names were unified into generic names by a text-mining ap-
proach. The paper does not provide details of this text-mining approach. The
paper does explain that the cleanup includes the correction of spelling errors.
For this purpose GNU Aspell is used to detect spelling errors and the suggested
corrections are manually confirmed by working pharmacists. It is unclear how
many spelling corrections were made. Finally, foods, beverages, treatments (e.g.
X-ray radiation), and unspecified names (e.g. beta-blockers) were removed. It is
unclear from the paper if this removal step is manual or automatic. The result
of the normalization activity is represented in the provenance graph by the node
C.FAERS.
Co-occurrence selection The paper mentions that after the drug name normal-
ization the dataset contains 22,017,956 co-occurrences of drugs and events. A
drugname and an adverse event co-occur if they are mentioned together in a
report. The activity of counting co-occurrences is modeled as an explicit step
and the output is the node with label D.co-occurrences.
Contingency table To compute the PRR values from the set of co-occurrences a
2x2 contingency table is required for each drug-adverse event pair. Populating
the table requires the selection of the required subsets of co-occurrences. The
graph contains activities to create the tables for 5-FU with Leukopenia and
Capecitabine with Leukopenia. The resulting tables are shown as the nodes
5FU-Leukopenia and Capecitabine-Leukopenia. The IMJS paper does not
explicitly contain the 2x2 table for any of the drug-adverse event pairs, but
using the values mentioned in the paper we can partially reconstruct the tables,
see Table 2. In this table the values in bold font come from the paper, the italic
ones can be trivially calculated from these. The question marks represent values
which we will try to reverse engineer in the next section.
5-FU All other drugs
Leukopenia 277 ? ?
All other reactions 40,007 ? ?
40,284 21,977,672 22,017,956
Capecitabine All other drugs
Leukopenia 115 ? ?
All other reactions 34,813 ? ?
34,928 21,983,028 22,017,956
Table 2. Partial 2x2 contingency tables for 5-FU - Leukopenia and Capecitabine -
Leukopenia from the numbers provided in the IJMS paper. The numbers in italic are
calculated from the numbers that are given in the paper.
PRR values The final PRR values and the results of the chi-squared test are
provided in the IMJS paper. In the provenance graph they are represented as
the end nodes, e.g. PRR 5FU-Leukopenia. Note that to recalculate the values for
the PRR and chi-squared tests we need to obtain the missing values in Table 2.
5 Reproduction experiment
We first tried to recalculate the missing numbers in the 2x2 contingency tables
using the information given in the paper. Next we tried to reproduce the subsets
of drug-adverse event pairs that underly the 2x2 co-occurrences using the original
FAERS data from the FDA website, and thus reproducing the entire workflow.
Further details of the reproduction are available at the Website accompanying
this paper http://www.few.vu.nl/~michielh/lisc2013/.
5.1 Missing numbers and formulas
Using the PRR values given in the paper and the PRR formula cited by the
paper, we should be able reconstruct the missing values from the 2x2 contingency
tables. Note that while we do not know values for b, the number of mentions of
an adverse event in co-occurrence with all other drugs, we do know the values
for (b+ d). Based on Eq. 1, we should thus be able to calculate the values for b
by using Eq. 3.
b =
a/(a+ c)
PRR
× (b+ d) (3)
Knowing b, we should also be able to compute the total number of mentions
of an adverse event in the database a + b. For example, using the PRR value
5-FU All other drugs
Leukopenia 277 28,585 28,862
All other reactions 40,007 21,949,087 21,989,094
40,284 21,977,672 22,017,956
Capecitabine All other drugs
Leukopenia 115 28,747 28,862
All other reactions 34,813 21,954,281 21,989,094
34,928 21,983,028 22,017,956
Table 3. Reproduction of 2x2 contingency tables for 5-FU - Leukopenia and
Capecitabine - Leukopenia.
for 5-FU (5.282) and the numbers from the partial contingency table, Table 2,
the total number of mentions of Leukopenia should be 28,887. Surprisingly, this
number is different when calculated from the PRR for Capecitabine (2.520),
namely 28,952. For the other adverse events mentioned in the paper we also
found a difference when calculated with the PRR of 5-FU or with the PRR of
Capecitabine. These differences are all bigger than can be explained by rounding
errors. After more in-depth literature study we discovered that different formulas
are used to calculate the PRR. For example, the IJMS paper also cites [7] that
uses the formula given in Eq. 4:
PRR2 =
a/(a+ c)
(a+ b)/(a+ b+ c+ d)
(4)
Unfortunately, we do not get a constant number for a + b with this formula
either. However, after some experimentation we discovered that with Eq. 5 we
achieve a constant number for the mentions of Leukopenia, 28,862. Also for the
other adverse events this formula results in a constant number. From this we
conclude that while Eq. 5 is given nor cited by the IMJS paper, it is most likely
the formula used to calculate all PRR values mentioned in the paper (!).
PRR3 =
a/c
(a+ b)/(a+ b+ c+ d)
(5)
Now that the total number of mentions of Leukopenia is known (a+b) we can
complete the 2x2 contingency tables, see Table 3. Using this table it is also
possible to, modulo rounding errors, successfully reproduce the values from the
chi-squared tests with Eq. 2. Now we know how to compute the basis statistics
reported by the paper, we can try to reproduce the entire experiment.
5.2 Workflow reproduction
As it is unclear how the drug name normalization was performed, we decided not
to reproduce this on the entire dataset. We focus on the two drugs mentioned in
the IMJS paper: 5-FU and Capecitabine. Our aim is to approximate the PRR
values for these drugs and Leukopenia. The provenance graph of our reproduc-
tion is available at http://www.few.vu.nl/~michielh/lisc2013/prov/. We
encourage the reader to access this graph. The prov:Entity nodes in this graph
are clickable and point to the underlying data. In this way we provide access to
the intermediate datasets, which is an essential ingredient to successful reproduc-
tion of computational workflows. Currently, we are investigating normalization
of all drug names in the FAERS dataset.
Original FDA datasources Similarly as the study reported in the IMJS paper
we downloaded the 24 quarterly dumps (from the beginning of 2004 to the end
of 2009) from the FDA website.
Report aggregation by conversion to RDF We choose to aggregate the quarterly
files into a single dataset by first converting them to RDF and then storing these
in a triple store. The total number of reports in our RDF dataset is 2,231,038,
this is 9 reports more than reported in the IMJS paper. It is unclear where
the difference comes from. We can, however, confirm that the conversion to
RDF did not alter the original reports, as the original CSV files combined also
contain 2,231,038 unique report identifiers13. The conversion from CSV to RDF
was performed using SWI-Prolog and the RDF conversion toolset14. Details of
the conversion, the resulting RDF and the SPARQL endpoint are available at
http://www.few.vu.nl/~michielh/lisc2013.
Duplicate removal The duplicate removal step was performed on the RDF dataset.
We first grouped all reports with the same case number and for each group se-
lected the report with the highest report identifier. We removed the other reports
from the database. The resulting dataset contains 1,664,078 reports, this is 142
less than reported in the IMJS paper. We can’t explain this difference.
Drug name normalization Instead of normalizing all the drug names, we tried
to find all the mentions for our drugs of interest: 5-FU and Capecitabine. We
explored four methods to find different mentions for these drug names.
1. We selected the mentions that contain the drug name itself. For Capecitabine
this returns many mentions of capecitabine, but also many variations such as
capecitabine tablet 1000 mg, capecitabine roche laboratories inc and capecitabine
2000 mg po as divided doses daily. In total we find 337 different mentions
containing Capecitabine.
13 The total number of unique report identifiers in the CSV files from the FDA is
computed with a unix bash script: cut -d$ -f1 DEMO0*.TXT | sort -u | wc -l
14 http://semanticweb.cs.vu.nl/xmlrdf/
2. We selected mentions of a brand name associated with the drug. For example,
Capecitabine is sold under the brand name Xeloda. To get the brand names
for a drug we used the Open Data Drug & Drug target Database, Drug-
bank15. For Capecitabine we found in Drugbank one brand name (Xeloda).
Using this brand name 14 mentions are found in the FAERS dataset. From
these mentions 4 already contain Capecitabine, e.g. xeloda capecitabine. For
5-FU Drugbank contains 25 brand names, such as Adrucil and Fluoroplex.
For 6 of these 25 brand names, additional mentions were found in the FAERS
dataset.
3. We used Drugbank to find synonyms associated with a drug name. For ex-
ample, Capecitabine is also known as R340. However, no mentions of this
synonym are found in the FAERS dataset. For 5-FU no synonyms are found
in Drugbank.
4. We selected mentions of drug names that were spelled differently. Similarly
as was reported in the IMJS paper we used GNU Aspell. Aspell contains dic-
tionaries for many languages, but these are not very useful for drug names.
Therefore, we created our own Aspell dictionary using the drug names men-
tioned in Drugbank. With this dictionary we generated spelling variations
for all drug mentions in the FAERS dataset. For each drug mention we
added the highest ranked suggestion as an alternative label to the database.
For example, capecitabine was suggested for the drug mention capecitabin
and capecitapine. When using these spelling suggestions we could retrieve
for Capecitabine another 30 different mentions. From these 10 already con-
tained the correct spelling, e.g. capeciabine capecitabine.
Co-occurrence selection Without drug name normalization our dataset contains
a total of 23,865,029 drug-adverse event co-occurrences, 1,847,073 more than
reported in the IMJS paper. This larger number of co-occurrences can be ex-
plained by the fact that we did not remove foods, beverages, treatments (e.g.
X-ray radiation), and unspecified names (e.g. beta-blockers), as was mentioned
in the IMJS paper. In addition, drug names for a single report may contain
multiple treatments each containing a different drug mention. For example, a re-
port may contain treatment with the mention capecitabine 500 MG and another
with the mention capecitabine 1000 MG. In other words, the patient received
two treatments, and in the second treatment the dosage of Capecitabine was
increased. Without drug name normalization these mentions are counted as two
co-occurrences, whereas after normalization they will be counted as a single co-
occurrence. Considering the formula for PRR in Eq. 5 this difference is reflected
in the denominator, the total number of co-occurrences (a+b+c+d) as well as
the total number of co-occurrences with a specific adverse event (a+b).
Contingency table Using the four methods to find drug mentions we selected
the set of co-occurrences corresponding to the cells of the 2x2 contingency. The
total number of co-occurrences with Leukopenia (a+b) that we found is 30,724.
15 http://www.drugbank.ca/
A difference of 1,862 with the number reported in the IMJS paper. This can
also be explained by the lack of drug name normalization. The total number
of co-occurrences with 5-FU is 42,115, 1831 more than reported in the IMJS
paper. For Capecitabine 37,973 co-occurrences are found, 3045 more than in
the IMJS paper. We conclude that the four drug name selection methods find
more mentions of the two drugs. Currently we are investigating if and why
drug mentions are falsely included. We found 289 co-occurrences for 5-FU with
Leukopenia. This is 12 more than reported in the IMJS paper. For Capecitabine
122 co-occurrences were found with Leukopenia, 7 more than the 115 reported
in the IMJS paper.
PRR values Using the values in the reproduced 2x2 contingency tables and Eq. 5
the PRR for 5-FU with Leukopenia is 5.367 compared to 5.282. The chi-squared
test is 1019.763 compared to 952.334. For Capecitabine with Leukopenia the
PRR is 2.503 compared to 2.520 in the IMJS paper, and the chi-squared test is
109.661 compared to 103.730.
6 Discussion
Reproducing the study described in the IMJS paper required substantial ef-
fort, it was difficult to verify the results of the intermediate datasets and al-
most impossible to analyze the differences in the reproduction. And this is all
despite the fact that the IMJS paper of the case study at first sight clearly de-
scribes the method and results. By formalizing the computational workflow in
PROV-O it became possible to systematically investigate the intermediate steps.
We believe that sharing such provenance graphs is a first step in simplifying the
reproduction of computational workflows. The next step is to also make the
content of the prov:Entity nodes available, and ultimately the computational
processes that underly the prov:Activity nodes. We hope that the clickable
provenance graph we made available at http://www.few.vu.nl/~michielh/
lisc2013/prov/ serves as an example.
Acknowledgments
This work was funded under the Dutch COMMIT program as part of the
Data2Semantics and SEALINCMedia projects.
References
1. H. Akil, M. E. Martone, and D. C. Van Essen. Challenges and opportunities in
mining neuroscience data. Science, 331(6018):708–712, 2011.
2. A. Bate, M. Lindquist, I. Edwards, S. Olsson, R. Orre, A. Lansner, and R. De Fre-
itas. A bayesian neural network method for adverse drug reaction signal generation.
European journal of clinical pharmacology, 54(4):315–321, 1998.
3. K. Belhajjame, O. Corcho, D. Garijo, J. Zhao, P. Missier, D. Newman, R. Palma,
S. Bechhofer, E. Garcia-Cuesta, J. Gmez-Prez, G. Klyne, K. Page, M. Roos,
J. Ruiz, S. Soiland-Reyes, L. Verdes-Montenegro, D. De Roure, and C. Goble.
A workflow-centric research objects: A first class citizen in the scholarly discourse.
In Proceedings of the ESWC2012 Workshop on the Future of Scholarly Communi-
cation in the Semantic Web (SePublica2012), Heraklion, Greece, May 2012.
4. E. Deelman, D. Gannon, M. Shields, and I. Taylor. Workflows and e-science: An
overview of workflow system features and capabilities. Future Generation Computer
Systems, 25(5):528–540, 2009.
5. S. J. W. Evans, P. C. Waller, and S. Davis. Use of proportional reporting ra-
tios (prrs) for signal generation from spontaneous adverse drug reaction reports.
Pharmacoepidemiology and Drug Safety, 10(6):483–486, 2001.
6. D. Garijo, P. Alper, K. Belhajjame, O. Corcho, Y. Gil, and C. Goble. Common
motifs in scientific workflows: An empirical analysis. In 8th IEEE International
Conference on eScience, USA, 2012. IEEE Computer Society Press.
7. A. Goald. Practical pharmacovigilance analysis strategies. Pharmacoepidemiology
and drug safety, 12(7):559–574, 2003.
8. C. Goble, R. Stevens, D. Hull, K. Wolstencroft, and R. Lopez. Data curation + pro-
cess curation=data integration + science. Briefings in Bioinformatics, 9(6):506–
517, 2008.
9. P. Groth and J. Frew. Proceedings of the 4th international conference on prove-
nance and annotation of data and processes. 2012.
10. P. Groth, Y. Gil, and S. Magliacane. Automatic metadata annotation through re-
constructing provenance. In Third International Workshop on the role of Semantic
Web in Provenance Management, ESWC 2012, 2012.
11. P. Groth and L. Moreau. PROV-Overview: An Overview of the PROV Family of
Documents. Working group note, W3C, Apr. 2013. http://www.w3.org/TR/2013/
NOTE-prov-overview-20130430/. Latest version available at http://www.w3.org/
TR/prov-overview/.
12. K. Kadoyama, I. Miki, T. Tamura, J. Brown, T. Sakaeda, and Y. Okuno. Adverse
event profiles of 5-fluorouracil and capecitabine: Data mining of the public version
of the fda adverse event reporting system, aers, and reproducibility of clinical
observations. International Journal of Medical Sciences, 9(1):33–39, 2012.
13. M. Liu, M. E. Matheny, Y. Hu, and H. Xu. Data mining methodologies for phar-
macovigilance. ACM SIGKDD Explorations Newsletter, 14(1):35–42, 2012.
14. J. P. Mesirov. Accessible reproducible research. Science, 327(5964):415–416, 2010.
15. H. A. Piwowar, R. S. Day, and D. B. Fridsma. Sharing detailed research data is
associated with increased citation rate. PloS one, 2(3):e308, Jan. 2007.
16. K. Rothman, S. Lanes, and S. Sacks. The reporting odds ratio and its advan-
tages over the proportional reporting ratio. Pharmacoepidemiology and drug safety,
13(8):519–523, 2004.
17. A. Szarfman, S. Machado, and R. O’Neill. Use of screening algorithms and com-
puter systems to efficiently signal higher-than-expected combinations of drugs and
events in the us fda’s spontaneous reports database. Drug safety : an international
journal of medical toxicology and drug experience, 25(6):381–392, 2002.
18. E. van Puijenbroek, A. Bate, H. Leufkens, M. Lindquist, R. Orre, and A. Egberts. A
comparison of measures of disproportionality for signal detection in spontaneous
reporting systems for adverse drug reactions. Pharmacoepidemiology and drug
safety, 11(1):3–10, 2002.
Appendix A
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Fig. 1. Reproduction of the provenance graph corresponding to the computational
workflow described in [12].
